<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148694</url>
  </required_header>
  <id_info>
    <org_study_id>04-183</org_study_id>
    <nct_id>NCT00148694</nct_id>
  </id_info>
  <brief_title>Preoperative Cisplatin in Early Stage Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Cisplatin in Early Stage ER-, PR-, HER-2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects the preoperative therapy cisplatin will
      have on patients with early stage estrogen receptor-negative (ER-), progesterone
      receptor-negative (PR-), or HER-2 negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before starting treatment patients will undergo placement of a clip into the tumor bed so the
      surgeon can locate the site of the tumor at the time of surgery.

      Patients will receive cisplatin intravenously once every three weeks for a total of 4 cycles
      or 12 weeks of treatment.

      After completion of cisplatin, patients will undergo surgery to remove any tumor that remains
      and to assess the tissue to see if tumor cells remain in the breast.

      Patients may receive a second breast MRI and biopsy 7-14 days after treatment begins to see
      whether we can identify tumors that will ultimately respond to cisplatin with a rapid
      evaluation.

      Patients will receive study treatment for approximately 12 weeks unless unacceptable toxicity
      occurs. After surgery patients will receive standard adjuvant therapy based on discussion
      with their physician. Follow-up progress will occur for several years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the clinical response after preoperative therapy with cisplatin in ER-, PR-, HER-2 negative early breast cancer patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pathologic complete response after preoperative therapy with cisplatin in this patient population</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 75mg/m2 q21 days x 4 pre-surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenously once every three weeks for a total of 12 weeks</description>
    <arm_group_label>Intervention single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All tumors must be ER-, PR- and HER-2 negative.

          -  Age &gt; 18 years

          -  ECOG performance status of less than or equal to 1

          -  Absolute neutrophil count (ANC) &gt; 1,500/mm3

          -  Hemoglobin &gt; 9mm/dl

          -  Platelets &gt; 100,000/mm3

          -  Creatinine &lt; 1.5mg/dl

          -  Glucose &lt; 200mg/dl

          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)

          -  SGOT &lt; 3.0 x ULN

        Exclusion Criteria:

          -  Prior chemotherapy treatment

          -  Pregnant or breast-feeding women

          -  History of serious illness, medical or psychiatric condition requiring medical
             management

          -  Uncontrolled infection

          -  Renal dysfunction

          -  Active or severe cardiovascular or pulmonary disease

          -  Peripheral neuropathy of any etiology that exceeds grade 1

          -  Prior history of malignancy

          -  Uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy E. Garber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.</citation>
    <PMID>20100965</PMID>
  </results_reference>
  <results_reference>
    <citation>Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22. Erratum in: Cancer Discov. 2013 Aug;3(8):952.</citation>
    <PMID>22576213</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Judy E. Garber, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cisplatin</keyword>
  <keyword>Early Stage Breast Cancer</keyword>
  <keyword>ER Negative Breast Cancer</keyword>
  <keyword>PR Negative Breast Cancer</keyword>
  <keyword>HER-2 Negative Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

